Produktdetaljer
Biographical note
Dr Eyal Herzog is a professor of Medicine at Icahn School of Medicine at Mount Sinai in New York where he was the director of Critical Care Cardiology and Echocardiography for over two decades at Mount Sinai- St. Luke’s Hospital. He is currently the Director of the Department of Cardiology at Hadassah Medical Center, The Hebrew University of Jerusalem, in Jerusalem, Israel.
Over the past three decades, Dr Herzog has developed highly respected methods for improving cardiovascular healthcare through the application of novel algorithmic pathways that simplify the diagnosis, treatment, and management of cardiovascular disease.
Dr Herzog is internationally recognized for his leadership in Critical Care Cardiology and Echocardiography. He had authored many textbooks, including the “The Cardiac Care Survival Guide” and “Herzog’s CCU book,” that became bestsellers in the United States and around the globe. Dr Herzog is an outstanding teacher. He has been awarded as “Teacher of the year” and “Physician of the year” numerous times by the Department of Medicine and the Division of Cardiology at Mount Sinai.
At Hadassah Medical Center in Jerusalem, Israel, Dr Herzog has developed a new and novel pathway for the diagnosis and management of pulmonary embolism, which serves as a theme for his book “Pulmonary Embolism”. He had also just completed a new book titeld: Cardiac electrosonography. The Cardiology department that he currently leads for the past 3 years in Jerusalem, Israel was named as “The World’s Best Specialized Hospitals” by Newsweek for these years.
This book reviews the diagnosis and management of cardiac amyloidosis. Systemic amyloidosis is a broad spectrum of diseases that results from misfolding of proteins that aggregate into amyloid fibrils. In cardiac amyloidosis, amyloid fibrils accumulate in the interstitial space between cardiac myocytes causing cellular injury and impairing cardiac function.
Cardiac Amyloidosis reviews the advances in cardiac imaging, diagnostic strategies and therapies available that have improved the recognition and treatment of cardiac amyloidosis. The contributors to this book have distilled the existing clinical guidelines into a novel and simple pathway to help healthcare providers diagnose and treat patients. Within this book they review each section of this pathway: suspicion, red flags, diagnosis, treatment and follow up. With current data suggesting that cardiac amyloidosis is more common than previously thought, this book is a timely addition to the literature and will be important for all healthcare professionals managing these patients.
Pathway for the diagnosis and management of CA.- Epidemiology and pathophysiology of CA.- Diagnosis of CA- ECG.- Diagnosis of CA- Echocardiography.- Diagnosis of CA- Nuclear imaging.- Diagnosis of CA- CMR.- Diagnosis of CA- Hematological testing.- Genetics testing in CA. Treatment of CA- heart failure.- Treatment of CA- Advanced heart failure management.- Treatment of CA- arrythmias management.- Treatment of CA- aortic stenosis management.- Treatment of CA- Disease modifying therapies.- Treatment of CA- New frontier and evolving therapies.- Hematological manifestations and treatment.- Neurology and CA.- Gastroenterology and CA.- Nephrology and CA.- Follow up of patients with CA.- Prognosis of patients with CA.- Case presentation of patients with CA using the CA pathway.
This book reviews the diagnosis and management of cardiac amyloidosis. Systemic amyloidosis is a broad spectrum of diseases that results from misfolding of proteins that aggregate into amyloid fibrils. In cardiac amyloidosis, amyloid fibrils accumulate in the interstitial space between cardiac myocytes causing cellular injury and impairing cardiac function.
Cardiac Amyloidosis reviews the advances in cardiac imaging, diagnostic strategies and therapies available that have improved the recognition and treatment of cardiac amyloidosis. The contributors to this book have distilled the existing clinical guidelines into a novel and simple pathway to help healthcare providers diagnose and treat patients. Within this book they review each section of this pathway: suspicion, red flags, diagnosis, treatment and follow up. With current data suggesting that cardiac amyloidosis is more common than previously thought, this book is a timely addition to the literature and will be important for all healthcare professionals managing these patients.
Produktdetaljer
Biographical note
Dr Eyal Herzog is a professor of Medicine at Icahn School of Medicine at Mount Sinai in New York where he was the director of Critical Care Cardiology and Echocardiography for over two decades at Mount Sinai- St. Luke’s Hospital. He is currently the Director of the Department of Cardiology at Hadassah Medical Center, The Hebrew University of Jerusalem, in Jerusalem, Israel.
Over the past three decades, Dr Herzog has developed highly respected methods for improving cardiovascular healthcare through the application of novel algorithmic pathways that simplify the diagnosis, treatment, and management of cardiovascular disease.
Dr Herzog is internationally recognized for his leadership in Critical Care Cardiology and Echocardiography. He had authored many textbooks, including the “The Cardiac Care Survival Guide” and “Herzog’s CCU book,” that became bestsellers in the United States and around the globe. Dr Herzog is an outstanding teacher. He has been awarded as “Teacher of the year” and “Physician of the year” numerous times by the Department of Medicine and the Division of Cardiology at Mount Sinai.
At Hadassah Medical Center in Jerusalem, Israel, Dr Herzog has developed a new and novel pathway for the diagnosis and management of pulmonary embolism, which serves as a theme for his book “Pulmonary Embolism”. He had also just completed a new book titeld: Cardiac electrosonography. The Cardiology department that he currently leads for the past 3 years in Jerusalem, Israel was named as “The World’s Best Specialized Hospitals” by Newsweek for these years.